Pharmacodynamic Study on Efficacy of Clopidogrel With St. John's Wort
Status:
Withdrawn
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether patients post PCI receiving clopidogrel who
are carriers of at least one CYP 2C19 loss-of-function allele may achieve improved
pharmacodynamic efficacy of clopidogrel when treated with the CYP 2C19 enzyme inducing agent,
St. John's wort, as compared with placebo.
Hypothesis
1. Reduced platelet reactivity is present in patients receiving St. John's wort as compared
to placebo when utilized in combination with clopidogrel
2. The combination or St. John's wort and clopidogrel results in enhanced platelet
inhibition
Phase:
N/A
Details
Lead Sponsor:
Lancaster General Hospital
Collaborators:
H G Barsumian MD Memorial Fund H. G. Barsumian Memorial Fund Louise von Hess Medical Research Institute